In Brief: Taro
This article was originally published in The Tan Sheet
Executive Summary
Taro: First Phase III trials of the generic drug company's prescription one-day treatment for vaginal yeast infections are complete. Taro plans to file an NDA in 1998 and is seeking a multinational partner for co-marketing of store brand and branded product. Taro is also talking to companies interested in its "NonSpil" technology for drug delivery; the pourable substance will remain in a spoon that has been turned upside down. The initial patent application was filed in April 1993...